Share this article on:

Changing Role of COX-2 Inhibitors in the Perioperative Period: Is Parecoxib Really the Answer?

Section Editor(s): White, Paul F.White, Paul F. MD, PhD, FANZCA

doi: 10.1213/01.ANE.0000158607.90390.01
Ambulatory Anesthesia: Editorial

Department of Anesthesiology and Pain Management University of Texas Southwestern Medical Center at Dallas, Texas

Endowment funds from the Margaret Milam McDermott Distinguished Chair in Anesthesiology at UT Southwestern Medical Center, and the White Mountain Institute in Los Altos, CA (Dr. White is the President), provided support for this project.

Accepted for publication January 18, 2005.

Address correspondence and reprint requests to Dr. Paul F. White, Professor and Holder of the Margaret Milam McDermott Distinguished Chair, Department of Anesthesiology and Pain Management, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390–9068. Address e-mail to

The current controversy regarding the risk of serious cardiovascular complications with long-term use of the cyclooxygenase (COX) type 2 inhibitors has raised medicolegal concerns in the anesthesia community about the continued use of these compounds in the perioperative period (1). Both the traditional nonsteroidal antiinflammatory drugs (NSAIDs) and the more highly selective COX-2 compounds have gained widespread popularity as analgesia adjuvants before and after surgery because of their ability to reduce the requirement for opioid analgesics and potentially facilitate the recovery process by decreasing opioid-related side effects (e.g., postoperative nausea, vomiting, ileus/constipation, urinary retention) (2).

The voluntary withdrawal of rofecoxib (Vioxx™) from the market by Merck would seem more logical if the drug were only used for treating chronic pain syndromes. However, numerous clinical studies over the past 5 years support the safety and efficacy of administering this long-acting COX-2 inhibitor before and after a wide variety of surgical procedures in order to minimize postoperative pain and improve early recovery (3–11). In fact, it had been suggested that rofecoxib was the most cost-effective drug in this class (12). Despite extensive use of rofecoxib in the perioperative period throughout the world, there have been no case reports of serious cardiovascular complications associated with its short-term use.

The availability of a parenterally active COX-2 inhibitor like parecoxib (Dynastat™) has been widely anticipated by anesthesiologists because it would allow greater flexibility for both treating and preventing pain in the postoperative period. Early clinical studies demonstrated that both pre- and/or postoperative use of parecoxib, a prodrug of valdecoxib (Bextra™) produced significant opioid-sparing effects and improved patient satisfaction with their pain management (13–16). Most of the placebo-controlled studies have suggested that use of parecoxib improved pain control and reduced postoperative side effects. However, investigators reported unexpected complications when parecoxib was used in combination with the oral formulation (valdecoxib) over a period of 14 days in patients with preexisting cardiovascular disease (17,18).

In the current issue of Anesthesia & Analgesia, Beaussier et al. (19) compared parecoxib to the IV prodrug of acetaminophen, propacetamol, in patients undergoing inguinal hernia repair. Although the intensity of pain at rest was less severe and a larger percentage of patients in the parecoxib group (87% vs 70%) rated their pain management as “good or excellent,” the postoperative opioid analgesic requirements were similar in both treatment groups. These findings suggest that parecoxib may not provide substantial benefits over acetaminophen in the postoperative period. However, the lack of a placebo control group makes it difficult to determine the clinical significance of these findings. Analogous to the earlier placebo-controlled studies involving parecoxib, this study also failed to examine clinically meaningful outcome variables (e.g., hospital discharge time, resumption of activities of daily living, return to work). Another potential limitation in the study design related to the fact that the study medication was administered at the end of surgery rather than prior to the start of the operation. Finally, the failure to utilize local anesthesia as part of a multimodal analgesic regimen further limits the clinical relevance of these findings.

In the study by Beaussier et al. (19), the dose of the acetaminophen prodrug was approximately 30 mg/kg IV. Since Korpela et al. (20) demonstrated that the opioid-sparing effects of acetaminophen were dose-dependent, it is possible that a larger dose of the acetaminophen prodrug (e.g., 40–60 mg/kg) would have been more effective in this acute pain model. Since an investigational IV formulation of acetaminophen is currently available for clinical testing (21), it would be interesting to compare maximally effective doses of the IV COX-2 inhibitor to IV acetaminophen in preventing pain after surgery.

Of interest, Ng et al. (22) recently reported that parecoxib (40 mg) was actually less effective than the nonselective NSAID ketorolac (30 mg) in preventing pain after gynecologic laparoscopic procedures. Although concerns have been raised about the use of the traditional NSAIDs such as ketorolac and ibuprofen in the perioperative period (23) because of the increased risk of bleeding (24,25), this remains a controversial subject (26,27). Controversy also exists regarding the risk of serious adverse effects of parecoxib (and valdecoxib) in patients with preexisting cardiovascular disease (17,18). Concerns have also been raised regarding the possible deleterious effects of COX-2 inhibitors on bone healing (28,29).

What then should be the role of the COX-2 inhibitors in the perioperative period? In light of the widespread clinical experience using COX-2 inhibitors in this setting without any apparent problem, and the extensive clinical research database supporting both the safety and the efficacy of short-term (3–5 days) perioperative use of these compounds for improving pain control (7,8), the COX-2 inhibitors should still be considered as part of a standard multimodal analgesic regimen. However, given the comparable analgesic efficacy and lower cost of traditional (nonselective) NSAIDS such as ibuprofen and ketorolac (22,26,30), these compounds may prove to be more cost-effective adjuvants in the perioperative period. Alternatively, other non-opioid analgesics such as acetaminophen (21,25,31,32) or gabapentin (33,34) may prove to be more cost-beneficial than the COX-2 inhibitors as part of a multimodal analgesic regimen in the future.

Finally, given the recent controversy involving the COX-2 inhibitors and the long-standing concerns regarding the perioperative use of traditional NSAIDs, it is clear that there remains a need for safer and more effective non-opioid analgesics to minimize pain and facilitate the recovery process after surgery. We hope that the study by Beaussier et al. (19) will serve to encourage other investigators to pursue clinical research on the role of non-opioid analgesics in the management of postoperative pain. Future comparative studies involving new non-opioid analgesics should emphasize clinically relevant outcome variables rather than simply examining their opioid-sparing properties and effects on pain scores.

Back to Top | Article Outline


1. Kondro W. Lawsuits mount in wake of rofecoxib (Vioxx) withdrawal. CMAJ 2004;171:1335.
2. White PF. The role of non-opioid analgesic techniques in the management of pain after ambulatory surgery. Anesth Analg 2002;94:577–85.
3. Reuben SS, Connelly NR. Postoperative analgesic effects of celecoxib or rofecoxib after spinal fusion surgery. Anesth Analg 2000;91:1221–5.
4. Reuben SS, Bhopatkar S, Maciolek H, et al. The preemptive analgesic effect of rofecoxib after ambulatory arthroscopic knee surgery. Anesth Analg 2002;94:55–9.
5. Issioui T, Klein KW, White PF, et al. Cost-efficacy of rofecoxib versus acetaminophen for preventing pain after ambulatory surgery. Anesthesiology 2002;97:931–7.
6. Turan A, Emet S, Karamanlioglu B, et al. Analgesic effects of rofecoxib in ear-nose-throat surgery. Anesth Analg 2002;95:1308–11.
7. Buvanendran A, Kroin JS, Tuman KJ, et al. Effects of perioperative administration of a selective cyclooxygenase 2 inhibitor on pain management and recovery of function after knee replacement: a randomized controlled trial. JAMA 2003;290:2411–8.
8. Ma H, Tang J, White PF, et al. Perioperative rofecoxib improves early recovery after outpatient herniorrhaphy. Anesth Analg 2004;98:970–5.
9. Sinatra RS, Shen QJ, Halaszynski T, et al. Preoperative rofecoxib oral suspension as an analgesic adjunct after lower abdominal surgery: the effects on effort-dependent pain and pulmonary function. Anesth Analg 2004;98:135–40.
10. Karamanlioglu B, Turan A, Memis D, Ture M. Preoperative oral rofecoxib reduces postoperative pain and tramadol consumption in patients after abdominal hysterectomy. Anesth Analg 2004;98:1039–43.
11. Cabrera MC, Schmied S, Derderian T, et al. Efficacy of oral rofecoxib versus intravenous ketoprofen as an adjuvant to PCA morphine after urologic surgery. Acta Anaesthesiol Scand 2004;48:1190–3.
12. Watcha MF, Issioui T, Klein KW, White PF. Costs and effectiveness of rofecoxib, celecoxib and acetaminophen for preventing pain after ambulatory otolaryngologic surgery. Anesth Analg 2003;96:987–94.
13. Desjardins PJ, Grossman EH, Kuss ME, et al. The injectable cyclooxygenase-2-specific inhibitor parecoxib sodium has analgesic efficacy when administered preoperatively. Anesth Analg 2001;93:721–7.
14. Tang J, Li S, White PF, et al. Effect of parecoxib, a novel intravenous cyclooxygenase-2 inhibitor, on the post-operative opioid requirement and quality of pain control. Anesthesiology 2002;96:1305–9.
15. Barton SF, Langeland FF, Snabes MC, et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute post-operative pain following gynecologic laparotomy surgery. Anesthesiology 2002;97:306–14.
16. Joshi GP, Viscusi ER, Gan TJ, et al. Effective treatment of laparoscopic cholecystectomy pain with intravenous followed by oral COX-2 specific inhibitor. Anesth Analg 2004;98:336–42.
17. Ott E, Nussmeier NA, Duke PC, et al. Efficacy and safety of cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003;125:1481–92.
18. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors paracoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352:1081–91.
19. Beaussier M, Weickmans H, Paugam C, et al. A randomized, double-blind comparison between parecoxib sodium and propacetamol for parenteral postoperative analgesia after inguinal hernia repair in adult patients. Anesth Analg 2005;100:1309–15.
20. Korpela R, Korvenoja P, Meretoja OA. Morphine-sparing effect of acetaminophen in pediatric day-case surgery. Anesthesiology 1999;91:442–7.
21. Moller PL, Juhl GI, Payen-Champenois C, et al. Intravenous acetaminophen (paracetamol): comparable analgesic efficacy, but better local safety than its prodrug, propacetamol, for postoperative pain after third molar surgery. Anesth Analg 2005. In press.
22. Ng A, Temple A, Smith G, Emembolu J. Early analgesic effects of parecoxib versus ketorolac following laparoscopic sterilization: a randomized controlled trial. Br J Anaesth 2004;92:846–9.
23. Souter AJ, Fredman B, White PF. Controversies in the perioperative use of nonsteroidal antiinflammatory drugs. Anesth Analg 1994;79:1178–90.
24. Gunter JB, Varughese AM, Harrington JF, et al. Recovery and complications after tonsillectomy in children: a comparison of ketorolac and morphine. Anesth Analg 1995;81:1136–41.
25. Rusy LM, Houck CS, Sullivan LJ, et al. A double-blind evaluation of ketorolac tromethamine versus acetaminophen in pediatric tonsillectomy: analgesia and bleeding. Anesth Analg 1995;80:226–9.
26. Pickering AE, Bridge HS, Nolan J, Stoddart PA. Double-blind, placebo-controlled analgesic study of ibuprofen or rofecoxib in combination with paracetamol for tonsillectomy in children. Br J Anaesth 2002;88:72–7.
27. Moiniche S, Romsing J, Dahl JB, Tramer MR. Nonsteroidal antiinflammatory drugs and the risk of operative site bleeding after tonsillectomy: a quantitative systematic review. Anesth Analg 2003;96:68–77.
28. Einhorn TA. COX-2: where are we in 2003?—The role of cyclooxygenase-2 in bone repair. Arthritis Res Ther 2003;5:5–7.
29. Seidenberg AB, An YH. Is there an inhibitory effect of COX-2 inhibitors on bone healing? Pharm Res 2004;50:151–6.
30. Dahl V, Dybvik T, Steen T, et al. Ibuprofen vs acetaminophen vs ibuprofen and acetaminophen after arthroscopically-assisted anterior cruciate ligament reconstruction. Eur J Anaesthesiol 2004;21:471–5.
31. Zhou TJ, Tang J, White PF. Propacetamol versus ketorolac for treatment of acute postoperative pain after total hip or knee replacement. Anesth Analg 2001;92:1569–75.
32. Hyllested M, Jones S, Pedersen JL, Kehlet H. Comparative effect of paracetamol, NSAIDs or their combination in postoperative pain management: a qualitative review. Br J Anaesth 2002;88:199–214.
33. Gilron I, Orr E, Tu D, et al. A placebo-controlled randomized clinical trial of perioperative administration of gabapentin, rofecoxib and their combination for spontaneous and movement-evoked pain after abdominal hysterectomy. Pain 2005;113:191–200
34. Turan A, White PF, Karamanlioglu B, et al. Gabapentin: an alternative to rofecoxib for perioperative pain management [abstract]? Eur J Anaesth 2005.
© 2005 International Anesthesia Research Society